GEN-MKT-18-7897-A
Mar 22, 2023 | Blogs, Discovery, Echo MS, Pharma | 0 comments
Read time: 1 min
Have you thought about introducing new technology into your high-throughput drug discovery lab? Here are 5 reasons the Echo® MS system could make a difference for you.
1. Increased sample throughput While a traditional fast LC-MS/MS run can take nearly 10 hours per plate, a 384-well plate of samples can take approximately 10 minutes per plate with the Echo® MS system. This means that study data can be available on the day samples are prepared and with the reliability of MS/MS.
2. Reduced carryover Moving away from LC-MS/MS eliminates the challenge of potential carryover. Acoustic Droplet Ejection technology removes the need for physical contact between the autosampler needle and the sample.
3. Method sensitivity Detection levels in the low nanomolar range are typically required in a high-throughput drug discovery lab and are readily achieved by the Echo® MS system.
4. Sample preparation savings Simply prepare the samples in an appropriate solvent and load them into a qualified microplate. Only 2.5 nL of precious sample is required for each analysis.
5. Data accuracy The Echo® MS system uses the trusted SCIEX Triple Quad 6500+ mass spectrometer to provide excellent Z’ values with MS/MS reliability.
Learn more about how the Echo® MS system can support high-throughput drug discovery in these technical notes Development of an acetylcholinesterase biochemical assay using the SCIEX Echo® MS system, Accelerating synthetic biology with very fast screening of metabolites in fermentation broth (sciex.com) might be of interest. Or visit sciex.com.
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network